David Jamieson

2.2k citations
43 papers · 1.5k · 1 hit paper · h-index 21

Impact in

  • Oncology top 5%
    • PARP inhibition in cancer therapy
    • Vascular Tumors and Angiosarcomas
    • Cancer Cells and Metastasis
    • Cancer Genomics and Diagnostics

Papers in

    • HER2/EGFR in Cancer Research 4
    • Drug Transport and Resistance Mechanisms 3
    • Cancer therapeutics and mechanisms 3
    • DNA Repair Mechanisms 2

David Jamieson

41 papers receiving 1.5k citations

David Jamieson's Hit Papers

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial 2017 · 345 citations
3450+3+6Years since publication100200300

Peers

David Jamieson
Comparison fields: 5 of 118
  • Oncology 592
  • Cancer Research 167
  • Pulmonary and Respiratory Medicine 322
  • Pharmacology 77
  • Toxicology 27
Replace Bin Xu with:
Bin Xu China
Christian M. Kurbacher Germany
Stephen Welch Canada
Minglun Li Germany
David Bomze Israel
Erika Ruíz‐García Mexico
Kari Kendra United States
Björn Erikstein Norway
Emma Dean United Kingdom
D. Vucicevic United States
David Jamieson relative to Bin Xu China Bin Xu's profile →
Citations per field
00.5×4.7×
Bin Xu · 1×
Citations per year

Countries citing papers authored by David Jamieson

Since Specialization
Citations

This map shows the geographic impact of David Jamieson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jamieson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jamieson more than expected).

Fields of papers citing papers by David Jamieson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Jamieson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jamieson. The network helps show where David Jamieson may publish in the future.

Co-authors

The 25 scholars most cited alongside David Jamieson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Jamieson Line = papers co-authored together David Jamieson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Hit paper breakdown →
2017345
2 2010144
3 2016127
4 2016100
5 201186
6 201768
7 201660
8 201651
9 202044
10 201643
11 201537
12 200735
13 201633
14 201232
15 201831
16 201930
17 201130
18 201430
19 201125
20 202120

About David Jamieson

David Jamieson is a scholar working on Oncology, Molecular Biology, Infectious Diseases, Pediatrics, Perinatology and Child Health and Radiology, Nuclear Medicine and Imaging, having authored 43 papers that have together received 1.5k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (4 papers), HER2/EGFR in Cancer Research (4 papers), HIV/AIDS Research and Interventions (4 papers), Global Maternal and Child Health (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Cancer therapeutics and mechanisms (3 papers), DNA Repair Mechanisms (2 papers) and Neuroblastoma Research and Treatments (2 papers). The work is most often cited by research in Oncology (592 citations), Cancer Research (167 citations), Pulmonary and Respiratory Medicine (322 citations), Pharmacology (77 citations) and Toxicology (27 citations). David Jamieson has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Alan V. Boddy, Mark Verrill, Gareth J. Veal, Scott Kellerman, Michael Cole, J Sludden, Nicola J. Curtin, Martin J. Griffin, Ruth Plummer and Julieann Sludden. Their work appears in journals such as British Journal of Cancer, Contraception, European Journal of Cancer, Journal of the International AIDS Society and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact